Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Prospects for predicting and stopping the development of type 1 of diabetes
Autore:
Gorus, FK; Pipeleers, DG;
Indirizzi:
Free Univ Brussels, Diabet Res Ctr, B-1090 Brussels, Belgium Free Univ Brussels Brussels Belgium B-1090 Ctr, B-1090 Brussels, Belgium
Titolo Testata:
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
fascicolo: 3, volume: 15, anno: 2001,
pagine: 371 - 389
SICI:
1521-690X(200109)15:3<371:PFPAST>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
BETA-CELL FUNCTION; ONSET IDDM PATIENTS; CLINICAL ONSET; INSULIN GENE; NOD MICE; AUTOIMMUNE-DISEASE; ACID DECARBOXYLASE; PROLONGED EXPOSURE; ORAL INSULIN; HIGH-RISK;
Keywords:
type 1 diabetes; autoantibodies; HLA genes; gender; body mass index; hormones; prevention;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
104
Recensione:
Indirizzi per estratti:
Indirizzo: Gorus, FK Free Univ Brussels, Diabet Res Ctr, Laarbeeklaan 103, B-1090 Brussels, Belgium Free Univ Brussels Laarbeeklaan 103 Brussels Belgium B-1090ium
Citazione:
F.K. Gorus e D.G. Pipeleers, "Prospects for predicting and stopping the development of type 1 of diabetes", BEST PRAC R, 15(3), 2001, pp. 371-389

Abstract

The prevention of diabetes and its devastating complications is the prime goal of diabetes care. In immune-mediated type 1 diabetes, beta cell destruction can be predicted with increasing confidence both before and after diagnosis, thus allowing the development of preventative strategies. Multicentre clinical trials with the natural products insulin and nicotinamide have been launched, but the results will only be available in a few years time. Meanwhile, observational studies in large representative risk groups can help to refine the selection of subjects with a more homogenous risk for betacell destruction, thereby reducing the need for large sample sizes. The comparison between biological markers and disease progression will help to define surrogate disease end-points that can be monitored before the hard clinical endpoints of hyperglycaemia or remission. These advances will facilitate the start of new pilot trials to identify relatively safe candidate interventions adapted to disease stage.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/01/20 alle ore 13:00:58